AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 18 analysts
Fundamentals
Fundamentals institutional score is 51 using growth durability 51.4.
Valuation
Valuation institutional score is 35 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 69 using mean target upside 10.1%; dispersion penalty 9.8; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 46 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. analyst consensus provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 22.4% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.55). Confidence: 84%.
Live forward EPS implies next-12-month EPS of ₹33.72. Applying the stock's normalized valuation corridor produces a fair range of ₹1,727.48 to ₹2,055.23, with base value near ₹1,890.68 (+31.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹33.72
Forward P/E
42.7x
Base Fair Value
₹1,890.68
Fair Range
₹1,727.48 - ₹2,055.23
Upside To Base
+31.4%
Estimate Source
Live forward EPS
Growth Estimate
-0.2%
5Y Average
50.11
Current
68.65
Overvalued
60.95
Undervalued
51.23
5Y Average
29.95
Current
41.04
Overvalued
35.54
Undervalued
27.30
5Y Average
6.03
Current
8.26
Overvalued
7.15
Undervalued
5.49
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 68.3x Fair | -13% vs avg | +1.4% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.8x Undervalued | -42% vs avg | +6.8% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 139.2x Premium | +76% vs avg | +47.9% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.3x Undervalued | -26% vs avg | +7.6% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 53.1x Undervalued | -33% vs avg | +12.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 158.6x Premium | +101% vs avg | +10.2% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 43.5x Undervalued | -45% vs avg | +95.4% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 64.8x Undervalued | -18% vs avg | +23.2% |
GLOBAL HEALTH LIMITED trades in line with peers (68.7x vs avg 78.9x), reflecting a fair valuation within the Hospitals & Diagnostic Centres cohort. Peers include FORTIS HEALTHCARE LTD, NARAYANA HRUDAYALAYA LTD., ASTER DM QUALITY CARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.08K CrJun 2026Latest net profit
₹137 CrJun 2026Latest EPS
₹5.11Jun 2026Net margin
21.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 551 | 580 | 565 | 724 | 611 | 665 | 812 | 803 | 882 | 926 | 940 | 961 | 1,079 |
| Expenses + | 435 | 452 | 439 | 560 | 479 | 514 | 611 | 608 | 688 | 734 | 766 | 767 | 849 |
| Operating Profit | 115 | 128 | 126 | 164 | 132 | 150 | 202 | 195 | 195 | 193 | 174 | 193 | 230 |
| OPM % | 21% | 22% | 22% | 23% | 22% | 23% | 25% | 24% | 22% | 21% | 19% | 20% | 21% |
| Other Income + | 27 | 26 | 23 | 30 | 27 | 24 | 19 | -24 | 43 | 39 | -11 | 36 | 24 |
| Interest | 6 | 6 | 6 | 10 | 6 | 5 | 8 | 7 | 6 | 9 | 13 | 13 | 16 |
| Depreciation | 20 | 22 | 22 | 35 | 23 | 25 | 37 | 38 | 33 | 37 | 48 | 52 | 55 |
| Profit before tax | 116 | 127 | 121 | 149 | 130 | 144 | 175 | 126 | 198 | 185 | 103 | 163 | 183 |
| Tax % | 26% | 25% | 28% | 26% | 26% | 27% | 25% | 26% | 23% | 24% | 22% | 24% | 25% |
| Net Profit + | 86 | 95 | 87 | 109 | 96 | 104 | 131 | 93 | 152 | 140 | 80 | 124 | 137 |
| EPS in Rs | 3.21 | 3.54 | 3.25 | 4.08 | 3.59 | 3.89 | 4.89 | 3.48 | 5.65 | 5.22 | 2.97 | 4.62 | 5.11 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Announcement under Regulation 30 (LODR)-Date of payment of Dividend